Cargando…
Inhibition of mirtazapine metabolism by Ecstasy (MDMA) in isolated perfused rat liver model
BACKGROUND: Nowadays MDMA (3,4-methylendioxymethamphetamine), known as ecstasy, is widely abused among the youth because of euphoria induction in acute exposure. However, abusers are predisposed to depression in chronic consumption of this illicit compound. Mirtazapine (MRZ), an antidepressant agent...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5490157/ https://www.ncbi.nlm.nih.gov/pubmed/28659160 http://dx.doi.org/10.1186/s40199-017-0183-z |
_version_ | 1783246929492180992 |
---|---|
author | Jamshidfar, Sanaz Ardakani, Yalda H. Lavasani, Hoda Rouini, Mohammadreza |
author_facet | Jamshidfar, Sanaz Ardakani, Yalda H. Lavasani, Hoda Rouini, Mohammadreza |
author_sort | Jamshidfar, Sanaz |
collection | PubMed |
description | BACKGROUND: Nowadays MDMA (3,4-methylendioxymethamphetamine), known as ecstasy, is widely abused among the youth because of euphoria induction in acute exposure. However, abusers are predisposed to depression in chronic consumption of this illicit compound. Mirtazapine (MRZ), an antidepressant agent, may be prescribed in MDMA-induced depression. MRZ is extensively metabolized in liver by CYP450 isoenzymes. 8-hydroxymirtazapine (8-OH) is mainly produced by CYP2D6. N-desmethylmirtazapine (NDES) is generated by CYP3A4. MDMA is also metabolized by the mentioned isoenzymes and demonstrates mechanism-based inhibition (MBI) in association with CYP2D6. Several studies revealed that MDMA showed inhibitory effects on CYP3A4. In the present study, our aim was to evaluate the impact of MDMA on the metabolism of MRZ in liver. Therefore, isolated perfused rat liver model was applied as our model of choice in this assessment. METHODS: The subjects of the study were categorized into two experimental groups. Rats in the control group received MRZ-containing Krebs-Henselit buffer (1 μg/ml). Rats in the treatment group received aqueous solution of 1 mg/ml MDMA (3 mg/kg) intraperitoneally 1 hour before receiving MRZ. Perfusate samples were analyzed by HPLC. RESULTS: Analyses of perfusate samples showed 80% increase in the parent drug concentrations and 50% decrease in the concentrations of both metabolites in our treatment group compared to the control group. In the treatment group compared to the control group, AUC((0–120)) of the parent drug demonstrated 50% increase and AUC((0–120)) of 8-OH and NDES showed 70% and 60% decrease, respectively. Observed decrease in metabolic ratios were 83% and 79% for 8-OH and NDES in treatment group compared to control group, respectively. Hepatic clearance (CL(h)) and intrinsic clearance (Cl(int)) showed 20% and 60% decrease in treatment group compared to control group. CONCLUSION: All findings prove the inhibitory effects of ecstasy on both CYP2D6 and CYP3A4 hepatic isoenzymes. In conclusion, this study is the first investigation of MRZ metabolism in presence of MDMA in isolated perfused rat liver model. GRAPHICAL ABSTRACT: [Image: see text] |
format | Online Article Text |
id | pubmed-5490157 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-54901572017-06-30 Inhibition of mirtazapine metabolism by Ecstasy (MDMA) in isolated perfused rat liver model Jamshidfar, Sanaz Ardakani, Yalda H. Lavasani, Hoda Rouini, Mohammadreza Daru Short Communication BACKGROUND: Nowadays MDMA (3,4-methylendioxymethamphetamine), known as ecstasy, is widely abused among the youth because of euphoria induction in acute exposure. However, abusers are predisposed to depression in chronic consumption of this illicit compound. Mirtazapine (MRZ), an antidepressant agent, may be prescribed in MDMA-induced depression. MRZ is extensively metabolized in liver by CYP450 isoenzymes. 8-hydroxymirtazapine (8-OH) is mainly produced by CYP2D6. N-desmethylmirtazapine (NDES) is generated by CYP3A4. MDMA is also metabolized by the mentioned isoenzymes and demonstrates mechanism-based inhibition (MBI) in association with CYP2D6. Several studies revealed that MDMA showed inhibitory effects on CYP3A4. In the present study, our aim was to evaluate the impact of MDMA on the metabolism of MRZ in liver. Therefore, isolated perfused rat liver model was applied as our model of choice in this assessment. METHODS: The subjects of the study were categorized into two experimental groups. Rats in the control group received MRZ-containing Krebs-Henselit buffer (1 μg/ml). Rats in the treatment group received aqueous solution of 1 mg/ml MDMA (3 mg/kg) intraperitoneally 1 hour before receiving MRZ. Perfusate samples were analyzed by HPLC. RESULTS: Analyses of perfusate samples showed 80% increase in the parent drug concentrations and 50% decrease in the concentrations of both metabolites in our treatment group compared to the control group. In the treatment group compared to the control group, AUC((0–120)) of the parent drug demonstrated 50% increase and AUC((0–120)) of 8-OH and NDES showed 70% and 60% decrease, respectively. Observed decrease in metabolic ratios were 83% and 79% for 8-OH and NDES in treatment group compared to control group, respectively. Hepatic clearance (CL(h)) and intrinsic clearance (Cl(int)) showed 20% and 60% decrease in treatment group compared to control group. CONCLUSION: All findings prove the inhibitory effects of ecstasy on both CYP2D6 and CYP3A4 hepatic isoenzymes. In conclusion, this study is the first investigation of MRZ metabolism in presence of MDMA in isolated perfused rat liver model. GRAPHICAL ABSTRACT: [Image: see text] BioMed Central 2017-06-28 /pmc/articles/PMC5490157/ /pubmed/28659160 http://dx.doi.org/10.1186/s40199-017-0183-z Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Short Communication Jamshidfar, Sanaz Ardakani, Yalda H. Lavasani, Hoda Rouini, Mohammadreza Inhibition of mirtazapine metabolism by Ecstasy (MDMA) in isolated perfused rat liver model |
title | Inhibition of mirtazapine metabolism by Ecstasy (MDMA) in isolated perfused rat liver model |
title_full | Inhibition of mirtazapine metabolism by Ecstasy (MDMA) in isolated perfused rat liver model |
title_fullStr | Inhibition of mirtazapine metabolism by Ecstasy (MDMA) in isolated perfused rat liver model |
title_full_unstemmed | Inhibition of mirtazapine metabolism by Ecstasy (MDMA) in isolated perfused rat liver model |
title_short | Inhibition of mirtazapine metabolism by Ecstasy (MDMA) in isolated perfused rat liver model |
title_sort | inhibition of mirtazapine metabolism by ecstasy (mdma) in isolated perfused rat liver model |
topic | Short Communication |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5490157/ https://www.ncbi.nlm.nih.gov/pubmed/28659160 http://dx.doi.org/10.1186/s40199-017-0183-z |
work_keys_str_mv | AT jamshidfarsanaz inhibitionofmirtazapinemetabolismbyecstasymdmainisolatedperfusedratlivermodel AT ardakaniyaldah inhibitionofmirtazapinemetabolismbyecstasymdmainisolatedperfusedratlivermodel AT lavasanihoda inhibitionofmirtazapinemetabolismbyecstasymdmainisolatedperfusedratlivermodel AT rouinimohammadreza inhibitionofmirtazapinemetabolismbyecstasymdmainisolatedperfusedratlivermodel |